Trial
NCT03759288
An Active and Placebo-Controlled Study of Brazikumab in Participants With Moderately to Severely Active Crohn's Disease
Phase IITERMINATEDOPERATIONALConfidence: HIGH
Sponsor
AstraZeneca
Collaborators
—
Condition
Crohn's Disease
Intervention
Brazikumab low dose
Why stopped
Strategic decision to discontinue the development of brazikumab in inflammatory bowel disease.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-06-23